Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia

Dahabreh, IJ; Zoi, K; Giannouli, S; Zoi, C; Loukopoulos, D; Voulgarelis, M

dc.contributor.author	Dahabreh, IJ	en
dc.contributor.author	Zoi, K	en
dc.contributor.author	Giannouli, S	en
dc.contributor.author	Zoi, C	en
dc.contributor.author	Loukopoulos, D	en
dc.contributor.author	Voulgarelis, M	en
dc.date.accessioned	2014-03-01T01:58:54Z
dc.date.available	2014-03-01T01:58:54Z
dc.date.issued	2009	en
dc.identifier.issn	0145-2126	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/28779
dc.subject	Essential thrombocythemia	en
dc.subject	JAK2 V617F	en
dc.subject	Thrombosis	en
dc.subject	Systematic review	en
dc.subject	Meta-analysis	en
dc.subject.classification	Oncology	en
dc.subject.classification	Hematology	en
dc.subject.other	CHRONIC MYELOPROLIFERATIVE DISORDERS	en
dc.subject.other	POLYCYTHEMIA-VERA	en
dc.subject.other	JAK2(V617F) MUTATION	en
dc.subject.other	ALLELE BURDEN	en
dc.subject.other	RISK-FACTORS	en
dc.subject.other	617V-GREATER-THAN-F MUTATION	en
dc.subject.other	LEUKOCYTE ACTIVATION	en
dc.subject.other	JAK2-V617F MUTATION	en
dc.subject.other	THROMBOSIS	en
dc.subject.other	MYELOFIBROSIS	en
dc.title	Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2009	en
heal.abstract	A systematic review and meta-analysis was carried out to compare the frequency of clinically significant outcomes between JAK2 V617F positive and wild type patients with essential thrombocythemia (ET). JAK2 V617F positivity in patients with ET was associated with a clear increase in the odds of thrombosis [OR = 1.83 (95% CI, 1.32-2.53), p < 0.0001], and much higher odds of transformation to polycythemia vera [OR = 7.67 (95% Cl, 2.04-28.87), p = 0.0009]. The mean difference of the white blood cell count between JAK2 positive and negative patients was associated with an increased odds ratio for thrombosis (p = 0.02). The JAK2 V617F mutation in patients with ET is associated with an increased risk of adverse cardiovascular outcomes via an increase in the leukocyte count. (C) 2008 Elsevier Ltd. All rights reserved.	en
heal.publisher	PERGAMON-ELSEVIER SCIENCE LTD	en
heal.journalName	LEUKEMIA RESEARCH	en
dc.identifier.isi	ISI:000261680400010	en
dc.identifier.volume	33	en
dc.identifier.issue	1	en
dc.identifier.spage	67	en
dc.identifier.epage	73	en